Gilead: A Poor Payback Period For Kite Pharma?

Published: Sep 12, 2017

With an experienced management team and the ability to produce large amounts of free cash flow over time, Gilead Sciences (NASDAQ:GILD) failed for several years to respond to the market sentiment that required the acquisition and development of new businesses. Only now, through the acquisition of Kite Pharma, the company has demonstrated to investors that it can once again be flexible and focus on the development of new products.

Back to news